Impact of lower vasopressor use on survival in patients with heart failure on ECMO
Association Between Vasopressor Exposure Levels and 30-Day Mortality in Patients Receiving ECMO Support for Cardiogenic Shock: A Prospective Multicenter Cohort Study
This study is testing if using less vasopressor medication can help adults with heart failure on ECMO survive better over 30 days.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 534 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Beijing Anzhen Hospital Academic / other |
| Locations | 1 site (Beijing, Beijing Municipality) |
| Trial ID | NCT06862700 on ClinicalTrials.gov |
What this trial studies
This observational study investigates the relationship between vasopressor exposure levels and outcomes in adults experiencing cardiogenic shock who are receiving venoarterial extracorporeal membrane oxygenation (VA-ECMO). It will enroll 534 patients across multiple centers, categorizing them into high-dose and low-dose vasopressor groups based on their Vasoactive-Inotropic Score. The primary focus is to determine if reduced vasopressor use can decrease 30-day mortality rates. Secondary outcomes will assess hospital survival, mechanical ventilation duration, and complications related to ECMO support.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older with cardiogenic shock requiring first-time VA-ECMO support.
Not a fit: Patients under 18 years, those with severe pulmonary hypertension, or those requiring vasopressors for non-shock reasons may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved survival rates for patients with cardiogenic shock receiving ECMO support.
How similar studies have performed: While the approach of reducing vasopressor use in ECMO patients is being explored, this specific study's focus on mortality outcomes is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adults (≥18 years) with cardiogenic shock requiring VA-ECMO support. * First-time ECMO initiation. * Venoarterial ECMO (VA-ECMO) as the initial mode. Exclusion Criteria: * Age \<18 years. * Severe pulmonary hypertension. * Vasopressor use for non-shock indications (e.g., bleeding, post-cardiopulmonary bypass vasoplegia). * Severe missing data.
Where this trial is running
Beijing, Beijing Municipality
- Beijing Anzhen Hospital — Beijing, Beijing Municipality, China (Recruiting)
Study contacts
- Study coordinator: Xiaotong Hou, MD
- Email: xt.hou@ccmu.edu.cn
- Phone: 010-64456631
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.